Compare Recursion Pharmaceuticals Inc (RXRX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while YieldMax Universe Fund of Option Income ETFs trades at $7.65. Which is the better fit depends on your goals.
| RXRX | YMAX | |
|---|---|---|
Market Cap | $1.78B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $6.79 | $13.26 |
52-Week Low | $2.84 | $7.27 |
Enterprise Value | $1.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
YMAX trades at $7.70, up 1.58% today, with a neutral technical signal and bearish moving averages. Recent news highlights weekly dividend distributions, though a 24/7 Wall Street article on July 14, 2026, notes shrinking payouts and a 1.33% fee structure. The stock lacks disclosed financial ratios, limiting fundamental clarity.
The outlook is mixed, with income appeal from dividends offset by fee concerns and opaque fundamentals. Risks include cost inefficiencies and reliance on market volatility for returns, while technicals suggest near-term consolidation around $8 support/resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
